Are activist shareholders poison for biotech?

Activist shareholder Carl Icahn has prompted fears that companies' ability to finance long-term research could be limited by the short-term investment horizons of shareholders like him, putting pressure on companies to boost their share prices quickly--sometimes at the expense of drug development. Report